Natixis Spring Works Therapeutics, Inc. Transaction History

Natixis

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 13, 2024	BUY	$18.94 - $37.24 $1.21 Million - $2.38 Million	63,800 New	63,800 $2.33 Million
Q2 2022 Aug 12, 2022	SELL	$18.36 - $60.07 $1.74 Million - $5.71 Million	-95,000 Closed	0 $0
Q1 2022 May 13, 2022	BUY	$48.97 - $65.46 $4.65 Million - $6.22 Million	95,000 New	95,000 $5.36 Million
Q4 2021 Feb 14, 2022	SELL	$53.3 - $75.84 $1.78 Million - $2.53 Million	-33,400 Closed	0 $0
Q3 2021 Nov 12, 2021	BUY	$62.66 - $88.26 $2.09 Million - $2.95 Million	33,400 New	33,400 $2.12 Million
Q2 2021 Aug 13, 2021	SELL	$67.45 - $85.63 $2.41 Million - $3.07 Million	-35,800 Closed	0 $0
Q1 2021 May 14, 2021	SELL	$65.1 - $93.59 $1.99 Million - $2.86 Million	-30,600 Reduced 46.08%	35,800 $2.63 Million
Q4 2020 Feb 12, 2021	BUY	$48.36 - $77.92 $3.21 Million - $5.17 Million	66,400 New	66,400 $4.82 Million

238

69.8M

144K

257K

Ticker SWTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 62,401,100
Market Cap $2.43B
Description
SpringWorks Therapeutics, Inc. acquires, develops, and commercializes medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is nirogacestat, an oral small molecule gamma secretase inhibitor that is in Phase III clinical trial for the treatment of desmoid tumors. The company is also deve...

Get notified when there are updates to the investment portfolio of Natixis, based on Form 13F filings with the SEC.

Stay updated on Natixis with notifications on news.